Skip to content

The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems

Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?

Health economics of disease-modifying therapy for multiple sclerosis in the United States

Era of biosimilars in rheumatology: reshaping the healthcare environment

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

A place for biosimilars in the changing multiple sclerosis treatment

Real-world evidence of a successful biosimilar adoption program

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability

Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis